Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEHART: MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Atezolizumab in Advanced Head and Neck Cancer
NCT04477759Phase 1Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Jan 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Medical College of Wisconsin. Primary endpoints: Incidence of Dose-Limiting Toxicities at 50 Gy With Concurrent Atezolizumab at 12 months, Incidence of Dose-Limiting Toxicities at 50 Gy at 12 months and 3 more. Started Jan 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04477759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477759.